# Mid-Link Group

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mid-link-group

- Industry: Biotechnology
- Headquarters: Tianjin, China
- Website: www.mid-link.net
- Total disclosed funding: $30M
- Latest round: Series B (Jul 30, 2022)
- Investors on record: 3

## About

Established in 2005 and based in Tianjin, China, Mid-Link Group is a medical regulations consulting and testing comprehensive service provider that focus on medical device, drug preclinical testing, animal experimentation and registration regulatory consultation. The company founder Xiaoming Hong  has 17 years experience in the field of medical device quality system and registration regulations consulting. Besides she is secretary general of China Medical Device Association and  professor of Shanghai University. The company established service outlets in Beijing, Tianjin, Shanghai, Jinan, Suzhou, Shenzhen, Houston and Vancouver.

The company's business covers product lifecycle services, service-based manufacturing, intelligent creation and third-party testing and certification. Mid-Link Group also provides biocompatibility testing, microbial testing, process validation and preclinical testing for customer.

## Funding rounds

- Series B, Jul 30, 2022, $15M — Legend Capital
- Series A, Jun 23, 2021, $15M — Watson Capital, Yushan Partners

## Investors

- Watson Capital (https://capitalatlas.ai/funds/watson-capital) — Series A
- Yushan Partners (https://capitalatlas.ai/funds/yushan-partners) — Series A
- Legend Capital — Series B